Los esteroides anabólicos androgénicos modifican persistentemente el perfil lipídico del usuario: reporte de caso


El objetivo del estudio fue mostrar una modificación duradera del perfil lipídico y los índices aterogénicos por el uso abusivo de esteroides anabólicos androgénicos (EAA) por parte de un fisicoculturista aficionado. Este estudio reporta un caso de un fisicoculturista no competitivo de 27 años con anormalidades severas en el perfil lipídico e índices aterogénicos. Hacía uso de esteroides anabólicos androgénicos y no tenía otros factores de riesgo de enfermedad cardíaca o factores de riesgo asociados. Después de algunas conferencias educativas, decidió continuar su entrenamiento sin usar esteroides anabólicos androgénicos ni drogas ergogénicas ilegales. El perfil lipídico y los índices aterogénicos volvieron a valores normales en la tercera prueba de laboratorio realizada cinco años después de su último ciclo de EAA. Abusar de los esteroides androgénicos anabólicos puede promover un mayor riesgo de enfermedad cardiovascular, un rasgo que puede persistir durante muchos años incluso después de suspender el uso de esteroides anabólicos androgénicos.

Palabras clave: Esteroides anabólicos androgénicos, Fisicoculturista, Enfermedades cardíacas, Anomalías cardiovasculares, Arteriosclerosis, HDL


Ahlgrim, C., & Guglin, M. (2009). Anabolics and cardiomyopathy in a bodybuilder: case report and literature review. Journal of cardiac failure, 15(6), 496-500. https://doi.org/10.1016/j.cardfail.2008.12.014

Ajayi, A.A., Mathur, R., & Halushka, P.V. (1995). Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation, 91(11), 2742-2747. https://doi.org/10.1161/01.CIR.91.11.2742

Angell, P., Chester, N., Green, D., Somauroo, J., Whyte, G., & George, K. (2012). Anabolic steroids and cardiovascular risk. Sports medicine, 42(2), 119-134. https://goo.gl/LR4H8V

Baggish, AL, Weiner, RB, Kanayama, G., Hudson, JI, Picard, MH, Hutter Jr, AM, & Pope Jr, HG (2010). Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation: Heart Failure, 3(4), 472-476. https://doi.org/10.1161/CIRCHEARTFAILURE.109.931063

Basaria, S., Wahlstrom, J.T., & Dobs, A.S. (2001). Anabolic-androgenic steroid therapy in the treatment of chronic diseases. The Journal of Clinical Endocrinology & Metabolism, 86(11), 5108-5117. https://doi.org/10.1210/jcem.86.11.7983

Blue, J.G., & Lombardo, J.A. (1999). Steroids and steroid-like compounds. Clinics in Sports Medicine, 18(3), 667-689. https://doi.org/10.1016/S0278-5919(05)70175-7

Castelli, W.P., Garrison, R.J., Wilson, P.W., Abbott, R.D., Kalousdian, S., & Kannel, W.B. (1986). Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. Jama, 256(20), 2835-2838. https://doi.org/10.1001jama.1986.03380200073024

Dobiasova, M., Urbanova, Z., & Samanek, M. (2005). Relations between particle size of HDL and LDL lipoproteins and cholesterol esterification rate. Physiol Res, 54(159), e65. http://www.biomed.cas.cz/physiolres/pdf/54/54_159.pdf

Far, H.R.M., Ågren, G., & Thiblin, I. (2012). Cardiac hypertrophy in deceased users of anabolic androgenic steroids: an investigation of autopsy findings. Cardiovascular Pathology, 21(4), 312-316. https://doi.org/10.1016/j.carpath.2011.10.002

Fernandez, M.L., & Webb, D. (2008). The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. Journal of the American College of Nutrition, 27(1), 1-5. https://doi.org/10.1080/07315724.2008.10719668

Gårevik, N., Strahm, E., Garle, M., Lundmark, J., Ståhle, L., Ekström, L., & Rane, A. (2011). Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids. The Journal of steroid biochemistry and molecular biology, 127(3-5), 295-300. https://doi.org/10.1016/j.jsbmb.2011.08.005

Gårevik, N., Rane, A., Björkhem-Bergman, L., Ekström, L. (2014). Effects of different doses of testosterone on gonadotropins, 25-hydroxyvitamin D3, and blood lipids in healthy men. Substance Abuse and Rehabilitation, 5, 121-127. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266340/.

Glazer, G. (1991). Atherogenic effects of anabolic steroids on serum lipid levels: a literature review. Archives of internal medicine, 151(10), 1925-1933. https://doi.org/10.1001/archinte.1991.00400100013003

Hengevoss, J., Piechotta, M., Müller, D., Hanft, F., Parr, MK Schänzer, W., Diel, P. (2015). Combined effects of androgen anabolic steroids and physical activity on the hypothalamic-pituitary-gonadal axis. Journal of Steroid Biochemistry and Molecular Biology, 150, 86–96. http://dx.doi.org/10.1016/j.jsbmb.2015.03.003.

Henning, A. (2017). Challenges to promoting health for amateur athletes through anti-doping policy. Drugs: Education, prevention and policy, 24(3), 306-313. https://doi.org/10.1080/09687637.2016.1208732

Hislop, M.S., Ratanjee, B.D., Soule, S.G., & Marais, A.D. (1999). Effects of anabolic-androgenic steroid use or gonadal testosterone suppression on serum leptin concentration in men. European journal of endocrinology, 141(1), 40-46. https://doi.org/10.1530/eje.0.1410040.

Ip, E.J., Barnett, M.J., Tenerowicz, M.J., & Perry, P.J. (2011). The Anabolic 500 survey: Characteristics of male users versus nonusers of anabolic‐androgenic steroids for strength training. Pharmacotherapy: The journal of human pharmacology and drug therapy, 31(8), 757-766. https://doi.org/10.1592/phco.31.8.757

Irwig, MS, Fleseriu, M., Jonklaas, J., Tritos, NA, Yuen, KCJ, Correa, R., Elhomsy, G., Gaarla, V., Jsaim, S., Soe, K., Baldeweg, SE, Boguszewski, CL, & Bancos, I. (2020). Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem. Endocrine Practice, 26(3), 340–353. https://doi.org/10.4158/ps-2019-0540

Kanayama, G., & Pope Jr, H.G. (2018). History and epidemiology of anabolic androgens in athletes and non-athletes. Molecular and Cellular Endocrinology, 464, 4-13. https://doi.org/10.1016/j.mce.2017.02.039

Karila, T., Laaksonen, R., Jokelainen, K., Himberg, J.J., & Seppälä, T. (1996). The effects of anabolic androgenic steroids on serum ubiquinone and dolichol levels among steroid abusers. Metabolism, 45(7), 844-847. https://doi.org/10.1016/S0026-0495(96)90157-2

Leit, R.A., Pope Jr, H.G., & Gray, J.J. (2001). Cultural expectations of muscularity in men: The evolution of Playgirl centerfolds. International Journal of eating disorders, 29(1), 90-93. https://psycnet.apa.org/record/2001-16082-015

Maravelias, C., Dona, A., Stefanidou, M., & Spiliopoulou, C. (2005). Adverse effects of anabolic steroids in athletes: a constant threat. Toxicology letters, 158(3), 167-175. https://doi.org/10.1016/j.toxlet.2005.06.005

Mann, S., Beedie, C., & Jimenez, A. (2014). Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Medicine, 44(2), 211–221. https://doi.org/10.1007/s40279-013-0110-5

Marqueti, R.C., Micocci, K.C., Leite, R.D., & Selistre-de-Araujo, H.S. (2012). Nandrolone inhibits MMP-2 in the left ventricle of rats. International journal of sports medicine, 33(03), 181-185. https://doi.org/10.1055/s-0031-1291252

Millán, J., Pintó, X., Muñoz, A., Zúñiga, M., Rubiés-Prat, J., Pallardo, LF, Masana, L, Mangas, A, Hernández-Mijares, A, González-Santos, P, Ascaso, JF, & Pedro-Botet, J. (2009). Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vascular health and risk management, 5, 757. https://doi.org/10.2147/VHRM.S6269

Montisci, M., El Mazloum, R., Cecchetto, G., Terranova, C., Ferrara, SD, Thiene, G., & Basso, C. (2012). Anabolic androgenic steroids abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases. Forensic science international, 217(1-3), e13-e18. https://doi.org/10.1016/j.forsciint.2011.10.032

Nieminen, MS, Rämö, MP, Viitasalo, M., Heikkilä, P., Karjalainen, J., Mäntysaari, M., & Heikkila, J. (1996). Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. European heart journal, 17(10), 1576-1583. https://doi.org/10.1093/oxfordjournals.eurheartj.a014724

Nwagha, U.I., Ikekpeazu, E.J., Ejezie, F.E., Neboh, E.E., & Maduka, I. (2010). Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. African health sciences, 10(3). https://goo.gl/UoXHkP

Palacios, A., Campfield, L.A., McClure, R.D., Steiner, B., & Swerdloff, R.S. (1983). Effect of testosterone enanthate on hematopoiesis in normal men. Fertility and Sterility, 40(1), 100-104. https://doi.org/10.1016/S0015-0282(16)47185-2

Parkinson, A.B., & Evans, N.A. (2006). Anabolic androgenic steroids: a survey of 500 users. Medicine and science in sports and exercise, 38(4), 644-651. https://doi.org/10.1249/01.mss.0000210194.56834.5d

Pertusi, R., Dickerman, R.D., & McConathy, W.J. (2001). Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: hepatitis or rhabdomyolysis? The Journal of the American Osteopathic Association, 101(7), 391-394. https://goo.gl/Vfrfta

Pettersson, J., Hindorf, U., Persson, P., Bengtsson, T., Malmqvist, U., Werkström, V., & Ekelund, M. (2008). Muscular exercise can cause highly pathological liver function tests in healthy men. British journal of clinical pharmacology, 65(2), 253-259. https://doi.org/10.1111/j.1365-2125.2007.03001.x

Pope, H.G., Kouri, E.M., & Hudson, J.I. (2000). Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Archives of general psychiatry, 57(2), 133-140. https://doi.org/10.1001/archpsyc.57.2.133

Pope Jr, H.G., Olivardia, R., Gruber, A., & Borowiecki, J. (1999). Evolving ideals of male body image as seen through action toys. International journal of eating disorders, 26(1), 65-72. https://doi.org/10.1002/(sici)1098-108x(199907)26:1%3C65::aid-eat8%3E3.0.co;2-d

Sagoe, D., Molde, H., Andreassen, C.S., Torsheim, T., & Pallesen, S. (2014). The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Annals of epidemiology, 24(5), 383-398. https://doi.org/10.1016/j.annepidem.2014.01.009

Santamarina, R.D., Besocke, A.G., Romano, L.M., Ioli, P.L., & Gonorazky, S.E. (2008). Ischemic stroke related to anabolic abuse. Clinical neuropharmacology, 31(2), 80-85. https://doi.org/10.1097/WNF.0b013e3180ed4485

Santora, LJ, Marin, J., Vangrow, J., Minegar, C., Robinson, M., Mora, J., & Frieds, G. (2006). Coronary calcification in body builders using anabolic steroids. Preventive cardiology, 9(4), 198-201. https://doi.org/10.1111/j.1559-4564.2006.05210.x

Schmidt, W., Biermann, B., Winchenbach, P., Lison, S., & Boning, D. (2000). How valid is the determination of hematocrit values to detect blood manipulations?. International journal of sports medicine, 21(2), 133-138. https://doi.org/10.1055/s-2000-8871.

Schwingel, PA, Cotrim, HP, Salles, BR, Almeida, CE, dos Santos Jr, CR, Nachef, B., Andrade, AR, & Zoppi, CC (2011). Anabolic‐androgenic steroids: A possible new risk factor of toxicant‐associated fatty liver disease. Liver International, 31(3), 348-353. https://doi.org/10.1111/j.1478-3231.2010.02346.x

Shahidi, N.T. (1973). Androgens and erythropoiesis. New England Journal of Medicine, 289(2), 72-80. https://doi.org/10.1056/NEJM197307122890205

Urhausen, A., Albers, T., & Kindermann, W. (2004). Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart, 90(5), 496-501. http://dx.doi.org/10.1136/hrt.2003.015719

Veras, K., Silva-Junior, F., L., Lima-Silva, A., E., De-Oliveira, F., R., & Pires, F.O. (2015) Impaired Physical Performance and Clinical Responses after a recreational bodybuilder’s self-administration of steroids: A Case Report. The World Journal of Men’s Health, 33(3), 209-213. http://dx.doi.org/10.5534/wjmh.2015.33.3.209

World Health Organization (1995). Physical status: The use of and interpretation of anthropometry, Report of a WHO Expert Committee. World Health Organization. https://doi.org/10.1002/(SICI)1520-6300(1996)8:6<786::AID-AJHB11>3.0.CO;2-I

Biografía del autor/a

Gustavo Casimiro-Lopes,


Gabriel Boaventura da Cunha,


Cómo citar
Casimiro-Lopes, G., & Cunha, G. B. da. (2022). Los esteroides anabólicos androgénicos modifican persistentemente el perfil lipídico del usuario: reporte de caso. Lecturas: Educación Física Y Deportes, 27(290), 134-145. https://doi.org/10.46642/efd.v27i290.2672
Estudios de Casos (Clínicos)